Dogwood Therapeutics to start phase 2b trial for Halneuron in chemotherapy-induced neuropathy
- Dogwood Therapeutics plans to begin dosing patients in a Phase 2b trial for Halneuron in Q1 2025.
- Halneuron is a Nav 1.7 specific voltage-gated sodium channel inhibitor aimed at treating chemotherapy-induced neuropathic pain.
- Previous trials showed Halneuron significantly reduced cancer-related pain with no addiction potential.
- Interim data from the Phase 2b trial is expected in the second half of 2025.
Read more
Adaptive Research expands into psychiatry with addition of Prodigy Psychiatric Group to clinical trial network
- Adaptive Research Inc. has expanded its clinical trial network into psychiatry by partnering with Prodigy Psychiatric Group.
- This collaboration will provide patients in community settings access to clinical trials for mental health treatments.
- Prodigy Psychiatric Group will receive comprehensive research support, including regulatory management and AI-enhanced patient recruitment.
- The partnership aims to improve diagnosis and treatment of conditions like ADHD, depression, and autism through clinical trials.
Read more
